The results revealed that glioblastomas of ArMRS high-risk group had significantly higher expression levels of CD44, CD48, CD276 (B7-H3), and PD1 (PDCD1) compared to low-risk group in the TCGA cohort (Figure 7A), suggesting higher ArMRS may indicate more abundant expression of immunotherapy targets. The gene discussed is CD48; the disease is glioblastoma.